Abstract
Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkins lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, limits the therapeutic efficacy of RIT in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed, and the clinical results of RIT in patients with hematological and various solid cancers (colorectal, ovarian, breast and renal carcinomas) are reviewed.
Keywords: renal cell cancer, colorectal cancer, G250, CD20, carcinoembryonic antigen, Non-Hodgkin's lymphoma, radionuclide, monoclonal antibodies, Radioimmunotherapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Volume: 7 Issue: 3
Author(s): Wim J. Oyen, E. J. Postema, Frans H. Corstens, Otto C. Boerman and Manuel J. Koppe
Affiliation:
Keywords: renal cell cancer, colorectal cancer, G250, CD20, carcinoembryonic antigen, Non-Hodgkin's lymphoma, radionuclide, monoclonal antibodies, Radioimmunotherapy
Abstract: Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkins lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, limits the therapeutic efficacy of RIT in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed, and the clinical results of RIT in patients with hematological and various solid cancers (colorectal, ovarian, breast and renal carcinomas) are reviewed.
Export Options
About this article
Cite this article as:
Oyen J. Wim, Postema J. E., Corstens H. Frans, Boerman C. Otto and Koppe J. Manuel, Radionuclide Therapy of Cancer with Radiolabeled Antibodies, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618126
DOI https://dx.doi.org/10.2174/187152007780618126 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serratia Type Pore Forming Toxins
Current Protein & Peptide Science HPC Analysis of Multiple Binding Sites Communication and Allosteric Modulations in Drug Design: The HSP Case Study
Current Drug Targets Development of Medical Images in Differentiating Benign from Malignant Thyroid Nodules
Current Medical Imaging Cardiac MRI in Infiltrative Disorders: A Concise Review
Current Cardiology Reviews New Biomarkers for Colon Cancer Diagnosis: A Review of Recent Patents
Recent Patents on Biomarkers Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry Absorption, Disposition and Pharmacokinetics of Nanoemulsions
Current Drug Metabolism Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Purine Analogues as Kinase Inhibitors: A Review
Recent Patents on Anti-Cancer Drug Discovery Development of Liposomes and Pseudovirions with Fusion Activity for Efficient Gene Delivery
Current Gene Therapy Synthesis of 2-(Bis (2-Chloroethyl)Amino)-N-(5-Substitutedphenyl)- 1,3,4- Thiadiazol-2-Yl)Acetohydrazide And Evaluation of Anticancer Activity
Current Bioactive Compounds Development and Production of Commercial Therapeutic Monoclonal Antibodies in Mammalian Cell Expression Systems: An Overview of the Current Upstream Technologies
Current Pharmaceutical Biotechnology Molecular Imaging with Nucleic Acid Aptamers
Current Medicinal Chemistry New Drugs, Old Fashioned Ways: ER Stress Induced Cell Death
Current Pharmaceutical Biotechnology Regeneration of the Gastric Mucosa and its Glands from Stem Cells
Current Medicinal Chemistry Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Gender Disparity in Pediatric Diseases
Current Molecular Medicine Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo
Current Drug Targets Synthesis of Nitroaromatic Compounds as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry